Infliximab: 12 years of experience

Arthritis Research and Therapy

Volumn 13, Issue SUPPL. 1, 2011, Pages

  Smolen, Josef S ^a   Emery, Paul ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Chapel Allerton Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; ARTHRITIS; ASPERGILLOSIS; BIOLOGICAL THERAPY; BONE DENSITY; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CORTICOSTEROID THERAPY; CROHN DISEASE; CRYPTOCOCCOSIS; DACTYLOLYSIS; DEMYELINATING DISEASE; DISEASE CONTROL; DISEASE COURSE; DISEASE REGISTRY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED MEDICINE; HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATOBILIARY DISEASE; HOT FLUSH; HUMAN; INFECTION; INFLAMMATION; INFUSION SITE REACTION; INJECTION SITE REACTION; JAUNDICE; JOINT INJURY; JOINT RADIOGRAPHY; LONG TERM CARE; LUPUS LIKE SYNDROME; LYMPHOMA; META ANALYSIS; MONOTHERAPY; MULTIPLE SCLEROSIS; MYCOSIS; NAIL; NAIL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PANCYTOPENIA; PNEUMOCYSTOSIS; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SACROILIITIS; SEIZURE; SIDE EFFECT; SKIN CANCER; SWEATING; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UVEITIS; VIRUS INFECTION; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79958145733     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/1478-6354-13-S1-S2     Document Type: Review

References (114)

1. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003, 2:473-488. 10.1038/nrd1109, 12776222.
2. Mielants H, Sieper J, Antoni CE, Van den Bosch F, van Vollenhoven RF. A new treatment approach paradigm in the management of spondyloarthropathies. Rheumatol News 2005, (Suppl):1-11.
3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907-916. 10.1056/NEJM200103223441207, 11259725.
4. Chen S, Gill MA, Luu CH, Takami S. Pain and rheumatoid arthritis: an update. Drug Topics 2000, 144:47-55.
5. Redlich K, Hayer S, Ricci R, David J-P, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Erwin EF, Schett G. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002, 110:1419-1427. 151809, 12438440.
6. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF-α antibody with interleukin-1 receptor antagonist. Eur Cytokine Netw 1995, 6:225-230.
7. Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, Gottlieb AB. Differential expression of phosphorylated NF-κB/RelA in normal and psoriatic epidermis and downregulation of NF-κB in response to treatment with etanercept. J Invest Dermatol 2005, 124:1275-1283. 10.1111/j.0022-202X.2005.23735.x, 15955104.
8. Gladman DD. Established criteria for disease controlling drugs in ankylosing spondylitis. Ann Rheum Dis 2003, 62:793-794. 10.1136/ard.62.9.793, 1754660, 12922946.
9. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006, 20:451-471. 10.1016/j.berh.2006.03.010, 16777576.
10. Lee JH, Jun JB, Jung S, Bae SC, Yoo DH, Kim TY, Kim SY, Kim TH. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci 2002, 17:669-673. 3054932, 12378021.
11. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 1996, 8:275-287. 10.1097/00002281-199607000-00003, 8864578.
12. Brophy S, Calin A. Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol 2001, 28:2283-2288.
13. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004, 34:585-592. 10.1016/j.semarthrit.2004.07.010, 15609262.
14. Vander B, Ribbens C, Boonen A, Mielants H, de Vlam K, Lenaerts J, Steinfeld S, Van den Bosch F, Dewulf L, Vastesaeger N. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007, 66:1072-1077. 10.1136/ard.2006.064543, 1954702, 17261531.
15. McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal appendage - implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009, 218:97-102. 10.1159/000182250, 19060455.
16. Serarslan G, Güler H, Karazincir S. The relationship between nail and distal phalangeal bone involvement severity in patients with psoriasis. Clin Rheumatol 2007, 26:1245-1247. 10.1007/s10067-006-0476-y, 17119859.
17. Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004, 43:790-794.
18. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002, 61:298-304. 10.1136/ard.61.4.298, 1754073, 11874829.
19. Wanders A, van der Heijde D, Landewe R, Behier J-M, Calin A, Olivieri I, Zeidler H, Dougados M. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005, 52:1756-1765. 10.1002/art.21054, 15934081.
20. Miceli-Richard C, Dougado M. NSAIDs in ankylosing spondylitis. Clin Exp Rheumatol 2002, 20(Suppl 28):S65-S66.
21. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. Arthritis Rheum 2005, 52:1000-1008. 10.1002/art.20990, 15818678.
22. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J. 'ASsessment in AS' International Working Group; European League Against Rheumatism: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006, 65:442-452. 10.1136/ard.2005.041137, 1798102, 16126791.
23. Kirwan JR, . Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995, 333:142-146. 10.1056/NEJM199507203330302, 7791815, Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
24. Mitka M. Early rheumatoid arthritis treatments weighed. JAMA 2005, 294:3073-3074. 10.1001/jama.294.24.3073, 16380583.
25. Kyle S, Chandler D, Griffiths CEM, Helliwell P, Lewis J, McInnes I, Oliver S, Symmons D, McHugh N, . British Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG) Guidelines for anti-TNF-α therapy in psoriatic arthritis. Rheumatology (Oxford) 2005, 44:390-397. British Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG).
26. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874. 10.1016/S0140-6736(07)60784-3, 17570481.
27. Amgen/Wyeth Pharmaceuticals. , http://www.enbrel.com
28. Abbott Laboratories: Five-year Data Demonstrate Initial Use of Abbott's Humira (Adalimumab) plus Methotrexate may Prevent Further Joint Damage in Early Rheumatoid Arthritis Patients. , http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0737.htm
29. Centocor, Inc. Remicade becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide. , http://www.merck.com/newsroom/news-release-archive/schering-plough-news-archive/all/releaseid=1077200.html
30. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110. 10.1016/S0140-6736(94)90628-9, 7934491.
31. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563. 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W, 9751087.
32. Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, . Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602. 10.1056/NEJM200011303432202, 11096166, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
33. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE, . ATTRACT Study Group Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical response. Arthritis Rheum 2005, 52:1020-1030. 10.1002/art.20982, 15818697, ATTRACT Study Group.
34. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 2004, 50:1400-1411. 10.1002/art.20217, 15146409.
35. Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006, 54:3119-3125. 10.1002/art.22143, 17009230.
36. van der Heijde D, Klareskog L, Boers M, Landewé R, Codreanu C, Bolosiu HD, Pedersen R, Fatenejad S, . TEMPO Investigators Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005, 64:1582-1587. 10.1136/ard.2004.034371, 1755254, 15860509, TEMPO Investigators.
37. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpit KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259. 10.1056/NEJM199901283400401, 9920948.
38. Conaghan PG, Quinn MA, O'Connor P, Wakefield RJ, Karim Z, Emery P. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?. Arthritis Rheum 2002, 46:1971-1972. 10.1002/art.10274, 12124886.
39. Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF, . PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002, 29:667-677. PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial.
40. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE, . Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051-1065. 10.1002/art.20159, 15077287, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
41. van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D, Beutler A. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 56:2698-2707. 10.1002/art.22805, 17665424.
42. Braun J, Landewé R, Hermann K-G, Han J, Yan S, Williamson P, van der Heijde D, . ASSERT Study Group Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006, 54:1646-1652. 10.1002/art.21790, 16646033, ASSERT Study Group.
43. Braun J, Landewé R, Hermann KG, Deodhar A, Baker D, Han J, Xu W, Williamson P, van der Heijde D. Sustained reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab [abstract]. Ann Rheum Dis 2007, 66(Suppl II):64.
44. Maini R, St Clair W, Breedveld FC, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999, 354:1932-1939. 10.1016/S0140-6736(99)05246-0, 10622295.
45. St Clair EW, van de Heijde D, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D, . Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 2004, 50:3432-3443. 10.1002/art.20568, 15529377, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group.
46. Verstappen SMM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, Bijlsma JWJ, Lafeber FPJG, , . Utrecht Rheumatoid Arthritis Cohort Study Group (SRU), Utrecht Rheumatoid Arthritis Cohort Study Group (SRU) Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be detected by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 2006, 8:1-9. Utrecht Rheumatoid Arthritis Cohort Study Group (SRU), Utrecht Rheumatoid Arthritis Cohort Study Group (SRU).
47. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1114-1121.
48. Emery P, McInnes IB, van Vollenhoven R, Kraan MC. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:392-398.
49. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004, 50:709-715. 10.1002/art.20044, 15022309.
50. Smolen JS, van der Heijde D, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schif M, Baker D, Han C, Han J, Bala M, . Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum 2006, 54:702-710. 10.1002/art.21678, 16508926, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.
51. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Aletaha D, Baker D, Han J, Bala M, St Clair EW, . Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009, 68:823-827. 10.1136/ard.2008.090019, 18593759, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.
52. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, St Clair EW, Weisman M, Smolen J, Lipsky PE, Maini RN. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004, 63:149-155. 10.1136/ard.2003.013961, 1754899, 14722203.
53. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Arthritis Rheum 2005, 52:27-35. 10.1002/art.20712, 15641102.
54. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37. 10.1002/art.21519, 16385520.
55. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450. 10.1002/art.10308, 12115173.
56. Soubrier M, Puéchal X, Sibilia J, Mariette X, Meyer O, Combe B, Flipo RM, Mulleman D, Berenbaum F, Zarnitsky C, Schaeverbeke T, Fardellone P, Dougados M. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 2009, 48:1429-1434.
57. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA. Clinical and radiographic outcomes of four diferent treatment strategies in patients with early rheumatoid arthritis (the BeST study). Arthritis Rheum 2005, 52:3381-3390. 10.1002/art.21405, 16258899.
58. Van Der Kooij SM, Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJSM, Van Der Lubbe PAHM, De Beus WM, Grillet BAM, Ronday K, Huizinga TWJ, Breedveld FC, Dijkmans BAC, Allaart CF. Drug-free remission, functioning, and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis. Ann Rheum Disease 2009, 68:914-921.
59. van der Bijl AE, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, ten Wolde S, Han KH, van Krugten MV, Allaart CF, Breedveld FC, Dijkmans BAC. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arth Rheum 2007, 56:2129-2134.
60. Klarenbeek NB, Dirven L, Guler-Yuksel M, Gerards AH, Kerstens PJSM, Molenaar THE, Huizinga TWJ, Dijkmans BAC, Allaart CF. Clinical and radiological outcomes of four DAS-driven treatment strategies: 6-year results of the BeSt study. Presented at: American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ ARHP) Scientific Meeting, October 16-21, 2009, Philadelphia, Pennsylvania, USA [abstract]. Arthritis Rheum 2009, 60(Suppl 10).
61. Vander B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 2006, 8:R112. 10.1186/ar2001, 1779428, 16978395.
62. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 2005, 118:515-520. 10.1016/j.amjmed.2005.01.029, 15866254.
63. Geborek P, Crnkic M, Petersson IF, Saxne T, . South Swedish Arthritis Treatment Group Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002, 61:793-798. 10.1136/ard.61.9.793, 1754224, 12176803, South Swedish Arthritis Treatment Group.
64. Wendling D, Materne GE, Michel F, Lohse A, Lehuede G, Toussirot E, Massol J, Woronoff-Lemsi MC. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine 2005, 72:309-312. 10.1016/j.jbspin.2004.08.008, 16038842.
65. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl 2):ii30-ii33. 1766750, 14532145.
66. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005, 64:1274-1279. 10.1136/ard.2004.031476, 1755655, 15708884.
67. Chevillotte-Maillard H, Ornetti P, Mistrih R, Sidot C, Dupuis J, Dellas JA, Tavernier C, Maillefert JF. Survival and safety of treatment with infliximab in the elderly population. Rheumatology (Oxford) 2005, 44:695-696.
68. Baeten D, De Keyser F, Mielants H, Veys EM. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2002, 16:537-549.
69. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52:2447-2451. 10.1002/art.21197, 16052578.
70. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187-1193. 10.1016/S0140-6736(02)08215-6, 11955536.
71. Braun J, Brandt J, Listing A, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005, 64:229-234. 10.1136/ard.2004.025130, 1755337, 15388511.
72. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J. Persistent clinical response to anti-TNF antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005, 44:670-676.
73. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J. Persistent clinical efficacy and safety of anti-tumour necrosis factor-α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008, 67:340-345.
74. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, . Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591. 10.1002/art.20852, 15692973, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
75. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 2007, 46:1450-1453.
76. van der Heijde D, Landewé R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008, 58:1324-1331. 10.1002/art.23471, 18438853.
77. Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, Cawkwell LS, Bennett A, McGonagle D, Emery P. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009, 60:946-954. 10.1002/art.24408, 19333933.
78. Rosenbaum JT. Acute anterior uveitis and spondyloarthropathies. Rheum Dis Clin North Am 1992, 18:143-151.
79. Mielants H, Veys EM, Cuvelier C, de Vos M. Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillière Clin Rheumatol 1996, 10:147-164. 10.1016/S0950-3579(96)80010-0, 21574554.
80. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007, 57:639-647. 10.1002/art.22669, 17471540.
81. Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:175-182. 10.1136/ard.2007.084426, 2605572, 18495735.
82. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227-1236. 10.1002/art.20967, 15818699.
83. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, . IMPACT 2 Trial Investigators Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150-1157. 10.1136/ard.2004.032268, 1755609, 15677701, IMPACT 2 Trial Investigators.
84. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C, . IMPACT 2 Study Group Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007, 66:498-505. 1856065, 17114188, IMPACT 2 Study Group.
85. Kavanaugh A, Antoni CE, Gladman DD, Wassenberg S, Zhou B, Beutler A, Keenan G, Burmester G, Furst DE, Weisman MH, Kalden JR, Smolen J, van der Heijde D. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006, 65:1038-1043. 10.1136/ard.2005.045658, 1798249, 16439444.
86. Krueger GG, Antoni C, Bala M, Yan S, Zhao N, Beutler A, Guzzo C, Kavanaugh A. The correlation of skin and joint response in patients with psoriatic arthritis treated with infliximab [abstract]. Ann Rheum Dis 2005, 64(Suppl III):319.
87. Rich P, Griffiths CEM, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008, 58:224-231. 10.1016/j.jaad.2007.07.042, 18083272.
88. Raffayova H, Kungurov N, Kubanova A, Baranauskaite A, Venalis A, Helmle L, Srinivasan S, Nasonov E. A randomized, multicenter, international, open-label study of infliximab plus methotrexate versus methotrexate alone for the treatment of methotrexate-naïve subjects with early, severe psoriatic arthritis (RESPOND trial). Presented at: American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ ARHP) Scientific Meeting, October 16-21, 2009, Philadelphia, Pennsylvania, USA [abstract]. Arthritis Rheum 2009, 60(Suppl 10).
89. Remicade (Infliximab) Summary of Product Characteristics, November 2009. European Medicines Agency. , http://emc.medicines.org.uk/
90. Enbrel (Etanercept) Summary of Product Characteristics, July 2009. European Medicines Agency. , http://emc.medicines.org.uk/
91. Humira (Adalimumab) Summary of Product Characteristics, September 2009. European Medicines Agency. , http://emc.medicines.org.uk/
92. Gibofsky A, Palmer W, Keystone EC, Schiff MH, Feng JY, Baumgartner S, Markenson JA. Safety profiles of disease-modifying anti-rheumatic drugs and biologics in patients with rheumatoid arthritis: observations from the RADIUS registry. Presented at: American College of Rheumatology/ Association of Rheumatology Health Professionals (ACR/ARHP) Scientific Meeting, October 16-21, 2009, Philadelphia, Pennsylvania, USA [abstract]. Arthritis Rheum 2009, 60(Suppl 10).
93. Curtis JR, Chen L, Cush JJ, Dao KH, Delzell E, Furst DE, Greenberg J, Hochberg MC, Jain A, Kremer JM, Patkar N, Solomon DH. The risk for hospitalized and outpatient infections related to anti-TNF therapy and newer biologics. Presented at: American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Scientific Meeting, October 16-21, 2009, Philadelphia, Pennsylvania, USA [abstract]. Arthritis Rheum 2009, 60(Suppl 10).
94. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register: Rates of serious infection, including site-specif c and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368-2376. 10.1002/art.21978, 16868999.
95. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X, . Research Axed on Tolerance of Biotherapies Group Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009, 60:1884-1894. erratum Arthritis Rheum 2009, 60:2540, 10.1002/art.24632, 2921546, 19565495, Research Axed on Tolerance of Biotherapies Group.
96. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, Rahman MU, . START Study Group The safety of infliximab, compared with background treatments, among patients with rheumatoid arthritis and various comorbidities. Arthritis Rheum 2006, 54:1075-1086. 10.1002/art.21734, 16572442, START Study Group.
97. Keystone E. Advances in targeted therapy: safety of biological agents. Ann Rheum Dis 2003, 62(Suppl II):S34-S36.
98. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412. 10.1002/art.21386, 16255017.
99. Keystone E. Safety of biologic therapies - an update. J Rheumatol 2005, 32(Suppl 74):8-12.
100. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-α antagonists. Drug Safe 2004, 27:307-324.
101. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, Klareskog L. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54:692-701. 10.1002/art.21675, 16508929.
102. Periodic Safety Update Report (PSUR) 18. 2008, Horsham, PA: Centocor, Inc..
103. Remicade (infliximab) Summary of Clinical Safety. July 2004 and August 2005, 244-254. Module 2.7.4. Horsham, PA: Centocor, Inc..
104. Wiens A, Correr CJ, Venson R, Grochocki MC, Otuki MF, Pontarolo R. A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol 2009, 28:1365-1373. 10.1007/s10067-009-1233-9, 19771491.
105. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009, 181:787-796. 2780484, 19884297.
106. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008, 214:149-160. 10.1002/path.2287, 18161752.
107. Giardina AR, Ferrante A, Ciccia F, Impastato R, Miceli MC, Principato A, Triolo G. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int 2010, 30:1437-1440. 10.1007/s00296-009-1157-3, 19851772.
108. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a 3-month, randomized, placebo-controlled trial. Arthritis Rheum 2003, 48:2224-2233. 10.1002/art.11104, 12905476.
109. Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU. GO-AFTER Study Investigators: Golimumab in patients with active rheumatoid arthritis after treatment with TNF-α inhibitors (GO-AFTER study): a multicentre, randomized, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374:210-221. 10.1016/S0140-6736(09)60506-7, 19560810.
110. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, , . REFLEX Trial Group, REFLEX Trial Group Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806. 10.1002/art.22025, 16947627, REFLEX Trial Group, REFLEX Trial Group.
111. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM. DANCER Study Group; DANCER Study Group: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum 2006, 54:1390-1400. 10.1002/art.21778, 16649186.
112. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kvien TK, Williams S, Hagerty D, Cravets MW, Shaw T. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009, 68:216-221. 10.1136/ard.2007.085787, 18388156.
113. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008, 67:547-554.
114. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [RADIATE study]. Ann Rheum Dis 2008, 67:1516-1523.